Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer

PURPOSE: This randomized phase III study was designed to compare the efficacy and safety of irinotecan plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC). MATERIALS AND METHODS: Patients were randomly assigned to receive IP,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Res Treat
Main Authors: Kim, Dong-Wan, Kim, Hoon-Gu, Kim, Joo-Hang, Park, Keunchil, Kim, Hoon-Kyo, Jang, Joung Soon, Kim, Bong-Seog, Kang, Jin-Hyoung, Lee, Kyung Hee, Kim, Sang-We, Ryoo, Hun Mo, Kim, Jin-Soo, Lee, Ki Hyeong, Kwon, Jung Hye, Choi, Jin-Hyuk, Shin, Sang Won, Hahn, Seokyung, Heo, Dae Seog
Formato: Artigo
Idioma:Inglês
Publicado: Korean Cancer Association 2019
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6334001/
https://ncbi.nlm.nih.gov/pubmed/29529858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.019
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares